One routine hepatitis B antibody may be more than a record of past infection: its quantity can reflect the host’s antiviral immune activity—and its meaning changes depending on the disease phase. The hepatitis B core protein, or HBcAg, is a highly immunogenic particulate antigen.

Nearly all patients with persistent or resolved HBV infection show seropositivity for anti-HBc, which appears early and is mostly present for life. Traditionally, anti-HBc has been treated as evidence of HBV infection. Over the last ten years, however, studies have revealed predictive value for quantitative anti-HBc, or qAnti-HBc, in treatment response and clinical outcome.

The review therefore presents qAnti-HBc as an indicator of the host’s HBV-specific immune response, linked with hepatitis activity and liver pathology, and examines its clinical value across chronic HBV phases. HBV is a major human pathogen that puts people at high risk of death from cirrhosis and liver cancer.

The World Health Organization estimates about 296 million people have chronic HBV infection, and about 800,000 die from related diseases each year. The hepatitis B vaccine has greatly reduced infection incidence, but current pegylated interferons and nucleoside or nucleotide analogues cannot effectively eradicate the virus, leaving many people at risk of liver disease.

A central reason treatment remains difficult is covalently closed circular DNA, or cccDNA, which persists in hepatocytes as the molecular basis for HBV persistence. Because current drugs have limitations and chronic HBV infection has a complex, long-term natural history, precise diagnostic markers are crucial for treatment selection, prognosis, and clinical management.

Recent work has introduced markers such as HBV RNA and HBcrAg, while also revealing new quantitative roles for established markers, including qHBsAg, qHBeAg, and qAnti-HBc. Clinical biomarkers describe HBV infection across dimensions connected to the viral life cycle and natural history.

ALT and AST indicate hepatic inflammation, but they are not specific to HBV. Viral markers mainly reflect viral loads, but directly measuring cccDNA requires liver biopsy samples and costly droplet digital PCR, limiting routine use.

Against that background, qAnti-HBc is presented as a universal surrogate marker for host antiviral immunity, with early work linking it to ALT activity and treatment response. Figure one maps biomarkers onto the HBV life cycle across hepatocytes, peripheral blood, and the immune system.

Its lower panels group them by disease severity, viral load—including cccDNA, HBsAg, HBV DNA, and HBV RNA—and host immune response, including anti-HBs, anti-HBe, anti-HBc, and T-cell responses. The authors emphasize that these markers capture different biological dimensions, while liver enzymes such as ALT and AST indicate inflammation but are not specific to HBV.

T cells could theoretically measure host anti-HBV immunity, but virus-specific T cells are typically exhausted in chronic infection, difficult to detect, and require intricate cell culture procedures. Among antibody markers, anti-HBs appears only after HBsAg loss, while anti-HBe is present in only some patients.

Anti-HBc is detectable in nearly all phases of HBV infection, making it a potential universal immune surrogate. HBcAg is an essential capsid component and is more immunogenic than HBeAg in stimulating cellular and humoral immunity. A qualitative anti-HBc assay cannot determine accurate differences between patients or changes during disease because the screening level requires serial dilutions or assays with wide dynamic ranges.

Figure two contrasts immune responses directed at hepatitis B core antigen, or HBcAg, with those directed at surface antigen, HBsAg. It depicts HBcAg-specific T cells as immune responsive and HBcAg-specific B cells progressing toward antibody-secreting plasma cells, whereas HBsAg-specific cells are associated with immune tolerance and an atypical memory phenotype.

The authors suggest that persistently high HBsAg may contribute to T-cell exhaustion and B-cell dysfunction, while core-specific responses support anti-HBc production through both T-dependent and T-independent pathways. In chronic HBV infection, people in the immune-active phase with active hepatitis typically have about tenfold higher qAnti-HBc levels than people in immune-tolerant or inactive-carrier phases without hepatitis.

qAnti-HBc correlates positively with ALT activity and with the histological severity of hepatic inflammation measured by liver biopsy. Its relationship with fibrosis is usually weaker than its relationship with inflammation.

The immune-active association is also seen in peripheral core-specific memory B cells, which occur at significantly higher frequencies than in immune-tolerant or inactive carriers. Together, the review summarizes high qAnti-HBc in immune-active CHB as associated with hepatic inflammation and ALT elevation, reflecting host anti-HBV immune activity.

Liver biopsy is the gold standard for diagnosing liver inflammation, but its invasive nature limits use. ALT can also miss inflammation: twenty to thirty percent of patients with normal ALT have moderate to severe liver inflammation. In one multicenter study of one thousand three hundred seventy-six untreated CHB patients with normal ALT, qAnti-HBc had a dose-responsive relationship with inflammation severity, with a cutoff near four point five log ten international units per milliliter.

Another study also linked elevated qAnti-HBc with significant liver injury in patients with normal ALT, but reported a lower cutoff of three point seven log ten international units per milliliter. In a long-term study of one hundred eighty-two HBeAg-positive children with normal ALT, baseline qAnti-HBc of five hundred international units per milliliter independently predicted spontaneous HBeAg seroconversion.

In those children, qAnti-HBc increased before ALT rose and before HBeAg seroclearance. Their lower qAnti-HBc than adults with CHB may suggest a less intense anti-HBV immune response in children. Extensive studies show that high qAnti-HBc strongly predicts HBeAg seroconversion, an event that often brings a favorable prognosis with less progressive liver inflammation and advanced liver disease.

In an early study, higher qAnti-HBc increased the probability of seroconversion after adefovir dipivoxil or pegylated interferon treatment. The reported cutoffs were twenty-nine thousand international units per milliliter for the adefovir group and nine thousand for the pegylated interferon group.

A separate multicenter cohort confirmed baseline qAnti-HBc as an independent predictor at treatment endpoint, using a cutoff of four point four log ten international units per milliliter. qAnti-HBc also predicts HBeAg seroconversion during the natural course of chronic HBV infection, not only in treatment cohorts.

High levels were independently associated with spontaneous seroconversion in the community-based REVEAL-HBV cohort. In HBeAg-positive children, higher qAnti-HBc predicted spontaneous seroconversion, while anti-HBc levels gradually increased with age and ongoing liver inflammation before seroconversion.

The prognostic meaning of qAnti-HBc is less settled in HBeAg-negative disease, and some studies suggest its direction differs from HBeAg-positive patients. In a retrospective REVEAL-HBV analysis of two thousand five hundred HBeAg-negative patients, qAnti-HBc below three point zero log ten international units per milliliter was independently associated with higher HBsAg seroclearance after twelve years: fifty-three percent versus nineteen point eight percent.

The authors note conflicting findings after nucleoside analogue treatment: lower qAnti-HBc at treatment end was associated with higher off-treatment relapse risk, and further studies are needed. Figure 3 schematically follows HBV DNA, HBsAg, qAnti-HBc, and ALT across chronic infection, separating HBeAg-positive and HBeAg-negative phases and possible outcomes such as inactivity, functional cure, or reactivation.

It emphasizes that qAnti-HBc has different implications by phase: higher levels are associated with immune activity during HBeAg-positive infection, while persistent low levels during virological control may accompany a greater likelihood of HBsAg loss. The figure therefore frames qAnti-HBc as a marker of host antiviral immunity and disease risk.

The relationship between qAnti-HBc and HBeAg seroconversion suggests a connection between activated core-specific immunity, HBeAg loss, and virological control. High HBsAg and HBeAg levels can induce T-cell exhaustion and immune tolerance during persistent HBV infection.

By contrast, HBcAg is more immunogenic and can activate HBcAg-directed and HBeAg cross-reactive B-cell responses. HBcAg-specific B cells can promote helper and cytotoxic T-cell responses, while high anti-HBc antibodies may also have a direct cytotoxic effect through Fc-mediated immune modulation, including complement-dependent cytotoxicity.

The resulting liver injury and hepatic inflammation help explain the relationship between qAnti-HBc and hepatitis activity. In chronic HBV infection, HBcAg-specific T cells are more activated, while HBsAg-specific B cells show an atypical memory phenotype and HBcAg-specific B cells are more activated.

For HBeAg-positive individuals, qAnti-HBc is a well-validated predictor of spontaneous and treatment-induced HBeAg seroconversion. Higher qAnti-HBc means a greater chance of achieving seroconversion. Across studies, four point zero to four point five log ten, or about ten thousand to thirty thousand international units per milliliter, may be preferable as a cutoff for adults with chronic hepatitis B.

For HBeAg-seronegative individuals with successful virological control, a persistent low qAnti-HBc level—possibly below one thousand international units per milliliter—is linked with a high probability of HBsAg loss. Regardless of HBeAg status or ALT activity, qAnti-HBc above four point zero or four point five log ten international units per milliliter correlates positively with activated host anti-HBV immune activity and the risk of significant hepatic inflammation.

The review concludes that qAnti-HBc is a surrogate marker for host anti-HBV immune activity in chronic HBV infection. Elevated qAnti-HBc-associated immunity is essential for immunological control during HBeAg-positive phases but signifies immune-escape hepatitis during HBeAg-negative phases.

Broad clinical use remains challenged by the absence of standardized automatic assays and well-validated cutoff indexes for different scenarios. Further studies are needed to clarify the immunological and virological mechanisms governing qAnti-HBc dynamics.

Quantitative anti-HBc can help distinguish immune activity, predict HBeAg seroconversion, and indicate possible hepatitis B control or inflammation. But standardized assays and phase-specific cutoffs are still needed before broad clinical use.